Harrow, Inc. Deferred Revenue
Harrow, Inc. (HROW) had Deferred Revenue of $2.50 thousand as of 2013-09-30, per its 10-Q filed 2013-11-06.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2013-11-06
- 2013-09-30: Deferred Revenue $2.50K.
- 2013-06-30: Deferred Revenue $1.67K.
- 2013-03-31: Deferred Revenue $833.00.
- 2012-12-31: Deferred Revenue $0.00.
| Period end | Deferred Revenue |
|---|---|
| 2013-09-30 | $2.50K 10-Q · filed 2013-11-06 |
| 2013-06-30 | $1.67K 10-Q · filed 2013-08-14 |
| 2013-03-31 | $833.00 10-Q · filed 2013-05-08 |
| 2012-12-31 | $0.00 10-Q · filed 2013-05-08 |
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 |
| 2011-12-31 | $100.00K 10-K · filed 2013-03-18 |
| 2011-09-30 | $100.00K 10-Q · filed 2012-02-23 |
| 2011-06-30 | $100.00K 10-Q · filed 2012-02-23 |
| 2010-12-31 | $80.00K 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |